Altimmune (NASDAQ:ALT) Director John Gill Buys 12,500 Shares

Altimmune, Inc. (NASDAQ:ALT) Director John Gill purchased 12,500 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were acquired at an average cost of $4.10 per share, with a total value of $51,250.00. Following the completion of the transaction, the director owned 12,500 shares in the company, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Altimmune Price Performance

Shares of NASDAQ ALT opened at $4.00 on Wednesday. The company has a quick ratio of 17.18, a current ratio of 17.18 and a debt-to-equity ratio of 0.08. Altimmune, Inc. has a twelve month low of $2.90 and a twelve month high of $8.05. The firm has a market cap of $417.36 million, a P/E ratio of -3.74 and a beta of -0.03. The company has a 50 day moving average of $4.52 and a 200 day moving average of $4.38.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%. As a group, research analysts expect that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Trading of Altimmune

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Altimmune by 23.3% during the third quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after buying an additional 1,206,514 shares during the period. Two Sigma Investments LP increased its position in shares of Altimmune by 356.6% during the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock worth $7,528,000 after purchasing an additional 1,559,562 shares in the last quarter. Geode Capital Management LLC raised its position in Altimmune by 13.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after purchasing an additional 228,995 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of Altimmune by 387.7% in the second quarter. Federated Hermes Inc. now owns 915,458 shares of the company’s stock valued at $3,543,000 after buying an additional 727,731 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Altimmune by 155.2% during the 2nd quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock worth $2,771,000 after acquiring an additional 435,467 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Trending Headlines about Altimmune

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Pemvidutide 48‑week IMPACT data showed durable, dose‑dependent antifibrotic signals, consistent safety, and meaningful weight loss (up to ~7.5% at 1.8 mg); Altimmune is positioned to advance a biopsy‑based Phase III (planned higher dose) and appears to have constructive regulatory alignment — a key clinical de‑risking step that can materially improve the stock’s outlook. Read More.
• Positive Sentiment: Director Jerome Benedict Durso bought 12,500 shares at an average $4.13 on Dec 22, signaling insider conviction and increasing insider ownership. SEC filing: Read More.
• Positive Sentiment: Director John Gill purchased 12,500 shares at an average $4.10 on Dec 23, another independent insider buy that reinforces management confidence in near‑term clinical and corporate prospects. SEC filing: Read More.
• Neutral Sentiment: On balance, sell‑side coverage remains mixed but constructive: the stock has an average analyst recommendation of “Moderate Buy,” which provides some institutional support but reflects varying views on commercialization and pricing risks. Read More.
• Negative Sentiment: Some sell ratings and cautious notes remain in the market (e.g., a reiterated Weiss Ratings “sell (d‑)”), underscoring the continued risk that clinical/regulatory or commercial execution could disappoint—factors that can cap near‑term upside despite positive data. Read More.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Monday. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Citizens Jmp cut their target price on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Monday, October 20th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.83.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.